November 11, 2020: Eli Lilly and Company will conduct a webcast on Friday, November 20, 2020 to provide an overview of the tirzepatide Phase 3 type 2 diabetes clinical trial program in preparation for five future Phase 3 top-line data disclosures. The webcast will begin at 11:00 a.m.
Eastern Standard Time and will review the trial designs and expected timing of the multiple readouts for the tirzepatide program.
Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly’s website at https://investor.lilly.com/webcasts-and-presentations.
A replay will also be available on the website following the conference call.
https://investor.lilly.com/news-releases/news-release-details/lilly-announces-webcast-provide-overview-tirzepatide-phase-3
